The implications of regional and national demographic projections for future GMS costs in Ireland through to 2026.
KeywordsHEALTH SERVICES AND THEIR MANAGEMENT
MetadataShow full item record
CitationConway, A. et al., 2014. The implications of regional and national demographic projections for future GMS costs in Ireland through to 2026. BMC Health Services Research, 14 (1), p 477
JournalBMC health services research
AbstractAs the health services in Ireland have become more resource-constrained, pressure has increased to reduce public spending on community drug schemes such as General Medical Services (GMS) drug prescribing and to understand current and future trends in prescribing. The GMS scheme covers approximately 37% of the Irish population in 2011 and entitles them, inter alia, to free prescription drugs and appliances. This paper projects the effects of future changes in population, coverage, claims rates and average claims cost on GMS costs in Ireland.
Data on GMS coverage, claims rates and average cost per claim are drawn from the Primary Care Reimbursement Service (PCRS) and combined with Central Statistics Office (CSO) (Regional and National Population Projections through to 2026). A Monte Carlo Model is used to simulate the effects of demographic change (by region, age, gender, coverage, claims rates and average claims cost) will have on GMS prescribing costs in 2016, 2021 and 2026 under different scenarios.
The Population of Ireland is projected to grow by 32% between 2007 and 2026 and by 96% for the over 70s. The Eastern region is estimated to grow by 3% over the lifetime of the projections at the expense of most other regions. The Monte Carlo simulations project that females will be a bigger driver of GMS costs than males. Midlands region will be the most expensive of the eight old health board regions. Those aged 70 and over and children under 11 will be significant drivers of GMS costs with the impending demographic changes. Overall GMS medicines costs are projected to rise to [euro sign]1.9bn by 2026.
Ireland's population will experience rapid growth over the next decade. Population growth coupled with an aging population will result in an increase in coverage rates, thus the projected increase in overall prescribing costs. Our projections and simulations map the likely evolution of GMS cost, given existing policies and demographic trends. These costs can be contained by government policy initiatives.
- Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database.
- Authors: Usher C, Tilson L, Bennett K, Barry M
- Issue date: 2012 Mar
- Ageing, health status and coverage rate effects on community prescription costs in Ireland.
- Authors: Kenneally M, Lynch B
- Issue date: 2018 Jun
- The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland.
- Authors: Tilson L, Bennett K, Barry M
- Issue date: 2005 Sep
- An evaluation of prescribing trends and patterns of claims within the Preferred Drugs Initiative in Ireland (2011-2016): an interrupted time-series study.
- Authors: McDowell R, Bennett K, Moriarty F, Clarke S, Barry M, Fahey T
- Issue date: 2018 Apr 20
- Psychostimulant prescribing trends in a paediatric population in Ireland: a national cohort study.
- Authors: Boland F, Galvin R, Reulbach U, Motterlini N, Kelly D, Bennett K, Fahey T
- Issue date: 2015 Sep 10